Friday, November 22, 2024
News

AI Aids Risk Prediction Classification for Prostate Cancer

Authors say this classification has the potential to minimize overtreatment and undertreatment

By Lori Solomon HealthDay Reporter

WEDNESDAY, Nov. 6, 2024 (HealthDay News) — Artificial intelligence (AI)-based risk classification improves prognostication with localized prostate cancer, according to a study published online Oct. 24 in JCO Precision Oncology.

Jonathan David Tward, M.D., Ph.D., from the University of Utah in Salt Lake City, and colleagues developed a clinically usable risk grouping system using multimodal AI (MMAI) models to risk-stratify localized prostate cancer. The analysis included 9,787 patients with localized prostate cancer from eight phase 3 trials treated with radiation therapy, androgen deprivation therapy, and/or chemotherapy followed for a median 7.9 years.

The researchers found that according to National Comprehensive Cancer Network (NCCN) risk categories, 30.4 percent of patients were low-risk, 25.5 percent intermediate-risk, and 44.1 percent high-risk. Based on MMAI risk classification, 43.5 percent of patients were low-risk, 34.6 percent intermediate-risk, and 21.8 percent high-risk, yielding reclassification of 1,039 patients (42.0 percent). The 10-year metastasis risks were comparable despite the MMAI low-risk group being larger than the NCCN low-risk group (1.7 percent for NCCN versus 3.2 percent for MMAI). For NCCN high-risk patients, the overall 10-year metastasis risk was 16.6 percent, with MMAI further stratifying this group into low-, intermediate-, and high-risk, with metastasis rates of 3.4, 8.2, and 26.3 percent, respectively.

“This approach aims to prevent both overtreatment and undertreatment in localized prostate cancer, facilitating shared decision-making,” the authors write.

Several authors disclosed ties to pharmaceutical and biotechnology companies.


Copyright © 2024 HealthDay. All rights reserved.

HealthDay.com
the authorHealthDay.com